Frontiers in psychiatry · 2025
Case Report: Development of persistent genital arousal disorder due to a possible combination of medications.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fiala Ludek, Lenz Jiří
Аннотация
OBJECTIVE: Persistent Genital Arousal Disorder (PGAD) is a rare and distressing condition characterized by persistent genital arousal in the absence of sexual desire. We present a unique case of a menopausal woman who developed PGAD after combined pharmacotherapy with trazodone, pregabalin, vaginal estriol, and depot medroxyprogesterone acetate (DMPA).
METHODS: The patient underwent comprehensive gynecological, neurological, and psychiatric evaluation. Menopausal status was confirmed by laboratory findings. A detailed pharmacological review was conducted to assess possible interactions affecting serotonergic, neuronal, and hormonal regulation.
RESULTS: PGAD symptoms emerged shortly after initiating the combination of these medications. Each drug has been individually associated with alterations in sexual function, but their concurrent use may have produced synergistic effects on neuroendocrine pathways. Gradual discontinuation of all medications resulted in complete remission of symptoms.
CONCLUSION: This case supports the hypothesis that combined modulation of serotonergic, neuronal, and hormonal systems can trigger PGAD in predisposed menopausal women. Recognition of potential pharmacological interactions is crucial for diagnosis and management of PGAD.
METHODS: The patient underwent comprehensive gynecological, neurological, and psychiatric evaluation. Menopausal status was confirmed by laboratory findings. A detailed pharmacological review was conducted to assess possible interactions affecting serotonergic, neuronal, and hormonal regulation.
RESULTS: PGAD symptoms emerged shortly after initiating the combination of these medications. Each drug has been individually associated with alterations in sexual function, but their concurrent use may have produced synergistic effects on neuroendocrine pathways. Gradual discontinuation of all medications resulted in complete remission of symptoms.
CONCLUSION: This case supports the hypothesis that combined modulation of serotonergic, neuronal, and hormonal systems can trigger PGAD in predisposed menopausal women. Recognition of potential pharmacological interactions is crucial for diagnosis and management of PGAD.